Barclays PLC Mersana Therapeutics, Inc. Transaction History

Barclays PLC

$377 Billion
Q3 2024

A detailed history of Barclays PLC transactions in Mersana Therapeutics, Inc. stock. As of the latest transaction made, Barclays PLC holds 494,516 shares of MRSN stock, worth $1.02 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares

494,516

Previous 494,516 -0.0%

Holding current value

$1.02 Million

Previous $934,000 -0.0%

% of portfolio

0.0%

Previous 0.0%

29 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2024 Nov 15, 2024	BUY	$1.23 - $2.25 $149,812 - $274,047	121,799 Added 32.68%	494,516 $934,000
Q2 2024 Aug 14, 2024	SELL	$2.0 - $4.45 $73,002 - $162,429	-36,501 Reduced 8.92%	372,717 $750,000
Q1 2024 May 15, 2024	BUY	$2.16 - $5.94 $555,452 - $1.53 Million	257,154 Added 169.11%	409,218 $1.83 Million
Q4 2023 Feb 15, 2024	BUY	$1.11 - $2.34 $130,880 - $275,909	117,910 Added 345.23%	152,064 $352,000
Q3 2023 Nov 07, 2023	SELL	$1.06 - $3.91 $161,941 - $597,350	-152,775 Reduced 81.73%	34,154 $43,000
Q2 2023 Aug 03, 2023	SELL	$3.08 - $9.55 $34,200 - $106,043	-11,104 Reduced 5.61%	186,929 $614,000
Q1 2023 May 04, 2023	SELL	$4.0 - $7.02 $136,220 - $239,066	-34,055 Reduced 14.67%	198,033 $815,000
Q4 2022 Feb 13, 2023	BUY	$5.65 - $7.86 $544,467 - $757,436	96,366 Added 71.0%	232,088 $1.36 Million
Q3 2022 Nov 03, 2022	BUY	$4.63 - $8.0 $470,570 - $813,080	101,635 Added 298.16%	135,722 $918,000
Q2 2022 Aug 12, 2022	SELL	$2.84 - $5.0 $21,263 - $37,435	-7,487 Reduced 18.01%	34,087 $157,000
Q1 2022 May 16, 2022	SELL	$3.74 - $6.63 $181,558 - $321,853	-48,545 Reduced 53.87%	41,574 $166,000
Q4 2021 Feb 14, 2022	BUY	$5.48 - $9.86 $312,924 - $563,035	57,103 Added 172.96%	90,119 $561,000
Q3 2021 Nov 09, 2021	SELL	$8.56 - $14.47 $208,427 - $352,330	-24,349 Reduced 42.45%	33,016 $312,000
Q2 2021 Aug 13, 2021	SELL	$13.28 - $18.07 $903,876 - $1.23 Million	-68,063 Reduced 54.26%	57,365 $778,000
Q1 2021 May 13, 2021	BUY	$15.31 - $26.52 $1.6 Million - $2.78 Million	104,804 Added 508.17%	125,428 $2.03 Million
Q4 2020 Feb 11, 2021	SELL	$16.84 - $27.59 $139,721 - $228,914	-8,297 Reduced 28.69%	20,624 $549,000
Q3 2020 Nov 12, 2020	BUY	$16.2 - $25.7 $12,490 - $19,814	771 Added 2.74%	28,921 $538,000
Q2 2020 Aug 12, 2020	BUY	$5.24 - $23.4 $11,554 - $51,597	2,205 Added 8.5%	28,150 $659,000
Q1 2020 May 13, 2020	SELL	$4.41 - $9.28 $76,275 - $160,506	-17,296 Reduced 40.0%	25,945 $151,000
Q4 2019 Feb 10, 2020	BUY	$1.45 - $6.73 $20,336 - $94,388	14,025 Added 48.0%	43,241 $248,000
Q3 2019 Nov 14, 2019	BUY	$1.54 - $4.2 $1,419 - $3,872	922 Added 3.26%	29,216 $46,000
Q2 2019 Aug 14, 2019	BUY	$3.84 - $6.4 $56,605 - $94,342	14,741 Added 108.77%	28,294 $115,000
Q1 2019 May 15, 2019	BUY	$3.51 - $7.3 $31,997 - $66,546	9,116 Added 205.45%	13,553 $71,000
Q4 2018 Feb 14, 2019	SELL	$3.45 - $9.72 $16,339 - $46,033	-4,736 Reduced 51.63%	4,437 $18,000
Q3 2018 Nov 14, 2018	BUY	$10.0 - $19.02 $65,570 - $124,714	6,557 Added 250.65%	9,173 $92,000
Q2 2018 Aug 14, 2018	SELL	$14.2 - $22.68 $23,316 - $37,240	-1,642 Reduced 38.56%	2,616 $46,000
Q1 2018 May 15, 2018	BUY	$13.56 - $18.48 $46,876 - $63,885	3,457 Added 431.59%	4,258 $68,000
Q4 2017 Feb 14, 2018	SELL	$14.95 - $19.9 $44,864 - $59,719	-3,001 Reduced 78.93%	801 $13,000
Q3 2017 Nov 14, 2017	BUY	$14.8 - $18.06 $56,269 - $68,664	3,802	3,802 $66,000

Others Institutions Holding MRSN

# of Institutions

121

Shares Held

116M

Call Options Held

233K

Put Options Held

457K

View Full List

About Mersana Therapeutics, Inc.

Ticker MRSN
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 97,169,296
Market Cap $201M
Description
Mersana Therapeutics, Inc., a clinical stage biopharmaceutical company, develops antibody drug conjugates (ADC) for cancer patients with unmet need. It develops XMT-1592, a Dolasynthen ADC targeting NaPi2b-expressing tumor cells, which is in phase I clinical trial for the treatment of ovarian cancer and NSCLC adenocarcinoma. The company also dev...

More about MRSN

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Barclays PLC, based on Form 13F filings with the SEC.

News

Stay updated on Barclays PLC with notifications on news.

Account